
REVATIO ORAL SUSPENSION Prescription & Dosage Information - MPR
Revatio Oral Suspension Dosage and Administration Adult ≥18yrs: 20mg three times daily. May titrate dose to a max of 80mg three times daily, if needed, based on symptoms and tolerability.
Sildenafil Oral Suspension: Package Insert / Prescribing Info
Jan 4, 2026 · Pediatric use information is approved for Viatris Specialty LLC's, REVATIO (sildenafil) for oral suspension. However, due to Viatris Specialty LLC's marketing exclusivity rights, this drug …
Revatio (Sildenafil) Dosage Guide: Forms, Adjustments, and More - GoodRx
Jul 2, 2024 · Revatio (sildenafil) is a medication that helps manage pulmonary arterial hypertension (PAH) in adults and children. It’s available as oral tablets, an oral liquid suspension, and an injection.
Sildenafil Suspension - Cleveland Clinic
SILDENAFIL (sil DEN a fil) treats pulmonary arterial hypertension (PAH), a condition that causes high blood pressure in the lungs. It works by relaxing your blood vessels and lowering the blood pressure …
Revatio - accessdata.fda.gov
REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise...
REVATIO is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was …
Sildenafil: MedlinePlus Drug Information
How should this medicine be used? Sildenafil comes as a tablet and suspension (liquid) to take by mouth. If you are taking sildenafil to treat erectile dysfunction, follow your doctor's directions and the …
Revatio 10 mg/ml powder for oral suspension - medicines
Revatio 10 mg/ml powder for oral suspension Active Ingredient: sildenafil citrate
Revatio: Package Insert / Prescribing Information / MOA
Jan 8, 2025 · Revatio package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
Since there are no clinical data on administration of REVATIO to patients with veno-occlusive disease, administration of REVATIO to such patients is not recommended. Should signs of pulmonary edema …